孟鲁司特联合布地奈德气雾剂吸入对过敏性鼻炎临床疗效研究

发布时间：2018-05-22 17:06

本文选题：孟鲁司特 + 布地奈德气雾剂　；参考：《北方药学》2016年11期

【摘要】：目的:观察孟鲁司特联合布地奈德气雾剂吸入治疗过敏性鼻炎的临床疗效。方法:选取2015年1月~2016年5月来我院进行治疗的过敏性鼻炎患者50例,根据治疗方法的不同随机分为两组,分别为观察组(25例)和对照组(25例),其中观察组采用孟鲁司特联合布地奈德气雾剂吸入的治疗方法,而对照组仅采用布地奈德气雾剂吸入的治疗方法,疗程为4周;比较两组治疗后的不良反应发生情况,同时对治疗前后两组免疫球蛋白Ig E的水平进行比较。结果:治疗4周后,观察组治疗的总有效率为96.00%,明显高于对照组的84.00%,差异显著(P0.05),两组不良反应发生率分别为8%和4%,差异不显著(P0.05);观察组的免疫球蛋白Ig E水平明显低于对照组,差异显著(P0.05)。结论:孟鲁司特联合布地奈德气雾剂吸入治疗过敏性鼻炎的方案可显著提高疗效,具有一定的协同作用,副作用小。
[Abstract]:Objective: to observe the clinical efficacy of montelukast combined with budesonide aerosol inhalation in the treatment of allergic rhinitis. Methods: fifty patients with allergic rhinitis treated in our hospital from January 2015 to May 2016 were randomly divided into two groups according to the different treatment methods. There were 25 cases in observation group (n = 25) and 25 cases in control group (n = 25). The observation group was treated with montelukast combined with budesonide aerosol inhalation, while the control group was treated with budesonide aerosol inhalation for 4 weeks. The incidence of adverse reactions and the level of immunoglobulin IgE before and after treatment were compared between the two groups. Results: after 4 weeks of treatment, the total effective rate of treatment in the observation group was 96.00, which was significantly higher than that in the control group (84.00), the difference was significant (P0.05). The incidence of adverse reactions in the two groups was 8% and 4%, respectively, the difference was not significant (P0.05), the level of immunoglobulin Ig E in the observation group was significantly lower than that in the control group. The difference was significant (P0.05). Conclusion: the combination of montelukast and budesonide aerosol inhalation in the treatment of allergic rhinitis can significantly improve the efficacy, has a certain synergistic effect, with little side effects.
【作者单位】：福建医科大学附属第一医院闽南分院耳鼻咽喉;
【分类号】：R765.21

【相似文献】